Skip to main content
Equibles
AMPH logo

AMPH · Amphastar Pharmaceuticals, Inc. · Metrics

Track AMPH — free

Use AMPH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AMPH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$23.54 +0.50 (+2.17%) At close · Sep 10
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$980.07M
Shares
42.54M

AMPH metrics

83 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$23.54
Market cap
$980.07M

Price action

20 metrics
Price change (1W)
-2.9%
Price change (30D)
+12.8%
Price change (3M)
+13.6%
Price change (6M)
+22.7%
Price change (YTD)
-14.0%
Price change (1Y)
-21.4%
Trailing year
Price change (5Y)
+27.6%
52-week high
$29.40
52-week low
$16.87
Change from 52-week high
-21.6%
Change from 52-week low
+36.6%
Annualized volatility
51.2%
Annualized volatility (3M)
40.9%
Beta
0.6
RSI (14D)
63.9
Price vs SMA 50
+11.7%
Price vs SMA 200
+2.4%
Avg volume (3M)
478,371
Relative volume
0.7
Average dollar volume
$9.77M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
42.54M

Valuation

12 metrics
P / E (TTM)
13.6
Trailing earnings · reciprocal yield 7.3%
PEG ratio
2.9
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.3×
reciprocal yield 74.5%
P / book
1.3
reciprocal yield 78.4%
FCF yield
15.6%
TTM · current market cap
Buyback yield
10.2%
P / FCF
6.4
reciprocal yield 15.6%
P / operating cash flow
5.3
reciprocal yield 18.8%
Earnings yield
8.0%

Historical valuation

8 metrics
P / E historical average (3Y)
14.4×
reciprocal yield 6.9%
P / E historical average (5Y)
20.9×
reciprocal yield 4.8%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
10.2%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
47.7%
Operating margin
15.7%
Trailing 12 months
Net margin
10.8%
Gross profit (TTM)
$348.11M
Operating profit (TTM)
$114.28M
Net income (TTM)
$78.55M
Trailing 12 months
Diluted EPS (TTM)
$1.69
FCF margin
20.9%
Effective tax rate
23.0%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$17.28

Growth

11 metrics
Revenue growth YoY
+5.4%
Year over year
Net income growth YoY
-2.2%
Revenue (TTM)
$730.02M
Trailing 12 months
EPS growth YoY
+4.7%
Shares change YoY
-8.1%
Year over year · fewer shares
Revenue CAGR (3Y)
+13.0%
Revenue CAGR (5Y)
+15.5%
EPS CAGR (3Y)
+5.3%
EPS CAGR (5Y)
+132.3%
FCF CAGR (3Y)
+23.0%
FCF CAGR (5Y)
+38.9%

Quality

14 metrics
Return on equity
10.2%
Return on assets
4.5%
Debt / equity
—
Current ratio
2.4
EBITDA (TTM)
$263.44M
Free cash flow (TTM)
$152.89M
Quick ratio
1.7
Interest coverage
4.4
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$223.61M
Total assets
$1.74B
Total debt
$619.71M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$184.61M
Capital expenditures (TTM)
$31.72M
R&D (TTM)
$94.57M
SG&A (TTM)
—
Stock compensation (TTM)
$28.87M
R&D / revenue
13.0%
Stock compensation / revenue
4.0%

Ownership (13F)

3 metrics
13F filers
210
13F filer change QoQ
-5
Institutional ownership
66.6%

Short interest

3 metrics
Short interest
12.1%
Latest settlement · 15.4 days to cover
Days to cover
15.4d
Short-squeeze score
71 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$421,044
Insider-sentiment score
37 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1297184 CUSIP 03209R103 13F (30d) 112 filings 112 filers Visit website Investor relations